***In situ* transcriptional profile of a germinal center plasmablastic burst hints at**

***MYD88*/*CD79B* mutants-enriched Diffuse Large B-cell Lymphomas.**

Vincenzo L'Imperio[1]*, Gaia Morello[2]*, Maria Carmela Vegliante[3], Valeria Cancila[2], Giorgio

Bertolazzi[2], Saveria Mazzara[4], Beatrice Belmonte[2], Piera Balzarini[5], Lilia Corral[6], Arianna Di

Napoli[7], Fabio Facchetti[8], Fabio Pagni[1]*, Claudio Tripodo[2,9]*

[1] Department of Medicine and Surgery, University of Milano-Bicocca, Pathology, San Gerardo
Hospital, Via G.B. Pergolesi 33, Monza, Italy.
[2] Tumor Immunology Unit, Department of Sciences for Health Promotion and Mother-Child
Care "G. D'Alessandro", University of Palermo, Palermo, Italy.
[3] Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
[4] Division of Diagnostic Haematopathology, European Institute of Oncology, Milan, Italy.
[5] Department of Molecular and Translational Medicine, University of Brescia, Piazzale Spedali
Civili 1, 25123, Brescia, Italy.
[6] Centro Ricerca Tettamanti, Pediatric Clinic, University of Milan Bicocca, San Gerardo
Hospital/Fondazione MBBM, Monza, Italy.
[7] Pathology Unit, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
[8] Pathology Unit, University of Brescia, Brescia, Italy.
[9] Tumor and Microenvironment Histopathology Unit, IFOM, the FIRC Institute of Molecular
Oncology, Milan, Italy.
* These Authors equally contributed

Correspondence:

Prof. Claudio Tripodo, Tumor Immunology Unit, University of Palermo, Corso Tukory

211, 90134, Palermo. Phone +3909123896211. Email: claudio.tripodo@unipa.it

Abstract

The germinal center (GC) reaction results in the selection of B-cells acquiring effector Ig secreting ability by progressing towards plasmablastic differentiation. This transition is associated with exclusion from the GC microenvironment. The aberrant expansion of plasmablastic elements within the GC fringes configures an atypical condition, the biological characteristics of which have not been defined yet. We investigated the *in situ* immunophenotypical and transcriptional characteristics of a non-clonal germinotropic expansion of plasmablastic elements (GEx) occurring in the tonsil of a young patient. Compared to neighboring GC and peri-follicular regions, the GEx showed a distinctive signature featuring key regulators of plasmacytic differentiation, cytokine signaling, and cell metabolism. The GEx signature was tested in the setting of diffuse large B-cell lymphoma (DLBCL) as a prototypical model of lymphomagenesis encompassing transformation at different stages of GC and post-GC functional differentiation. The signature outlined DLBCL clusters with different immune microenvironment composition and enrichment in genetic subtypes.

Significance: This report represents the first insight into the transcriptional features of a germinotropic plasmablastic burst, shedding light into the molecular hallmarks of B cells undergoing plasmablastic differentiation and aberrant expansion within the non-canonical setting of the GC microenvironment.

Running title: Spatial profiling of a germinotropic plasmablastic expansion

Keywords: digital spatial profiling, germinal center, plasmablast, diffuse large B-cell lymphoma.

Introduction

Within secondary lymphoid organs immune cells display topographic compartmentalization

underlying functional commitment towards different stages of immune response induction and

regulation. In lymphoid follicles, germinal centers (GCs) represent a complex specialized

microenvironment sustaining B-cell proliferative bursts underlying somatic hypermutation and

class-switch recombination of immunoglobulin (Ig) genes, communication with T cell subsets

with helping function (Tfh), and interplay with specialized mesenchymal scaffolds (i.e. FDCs)

(1). These events play through the dynamical iteration of elements between the dark (DZ),

intermediate and light (LZ) zones of the GC (2), eventually resulting in the differentiation and

displacement from the GC of cells acquiring effector capabilities through the synthesis and

secretion of Igs (i.e. plasmablasts and plasma cells) (3). Alterations in the topographic

compartmentalization of GC and extra-GC populations in lymphoid tissues are commonly

observed in the setting of lymphoproliferative diseases, where the accumulation of cells with

morphological or immunophenotypical features conflicting with their topographic localization

represents a hallmark of histopathological analyses. This assumption reached its highest

expression with the introduction of a diffuse large B cell lymphoma (DLBCL) prognostic sub-

classification based on the presumed cell-of-origin (COO), as determined by gene expression

profiling (GEP) (4-6).

We have investigated here an atypical germinotropic expansion of non-clonal, light-chain

restricted B cells with plasmablastic features confined to a single enlarged GC structure in the

tonsil of a young patient, through in situ immunolocalization analyses and high throughput

digital spatial profiling. Comparing the features of the atypical germinotropic expansion (GEx)

with those of topographically preserved DZ, LZ and peri-follicular (PERI) regions of interest

(ROIs) we identified a unique transcriptomic profile of the GEx ROIs featuring the

overexpression of transcripts involved in plasmacytoid differentiation, cytokine signaling, and

cell metabolism.

To probe the reflection of the identified transcriptional signature in a setting of B-cell

lymphomatous transformation embracing the full spectrum of GC- and post-GC differentiation,

the discriminative 20 genes were used to cluster a large cohort of diffuse large B-cell lymphoma

(DLBCL) transcriptomic data. The GEx signature highlighted two clusters with different

overall survival in DLBCL, where cases with the highest expression of GEx hallmark genes

were characterized by poorer prognosis.

Materials and methods

Clinical setting

This study started from the incidental finding of the reactive germinotropic plasmablastic

expansion described in the Results section, in the tonsil of a young patient who underwent

tonsillectomy for clinical hypertrophy. Sample was obtained and handled according to the

Declaration of Helsinki. Informed consent for surgery and histopathological studies was

obtained from the legal representatives. The case was included in the study 05/2018 approved

by the University of Palermo Institutional Review Board.

Histological, immunohistochemical and molecular analyses

Tonsillar tissue has been formalin-fixed and paraffin-embedded (FFPE) and 3 μm thick

sections have been stained with hematoxylin and eosin (H&E). IHC has been performed at the

Pathology Department of ASST Monza, San Gerardo Hospital, Monza, Italy using a Dako

Omnis platform (Dako, Denmark) using antibodies directed against CD20 (L26), CD3

(Polyclonal), Bcl2 (124), Bcl6 (PG-B6p), CD21, ki-67 (Mib-1), IRF4 (MUM1), CD10, CD30

(Ber-H2), CD138 (Mi15), HHV8 (13B10), kappa and lambda light chains. Double

immunohistochemistry has been performed for MUM1 and CD10 using 3-3'-diaminobenzidine (DAB) and 3-amino-9-ethylcarbazole (AEC) as chromogens, respectively. In situ fluorescence hybridization (FISH) study has been performed using a *IRF4/DUSP22* (6p25) Break Apart kit (Kreatech, Leica Biosystem, Germany) at the Pathology Department of Spedali Riuniti di Brescia. Quantitative evaluation of immunophenotypical markers was performed by applying the HALO image analysis software (v3.2.1851.229, Indica Labs) to regions selected on whole slide digital scans acquired using an Aperio CS2 slide scanner with the ImageScope software (v12.3.28013, Leica Biosystems, Germany).

Quantitative polymerase chain reaction (Q-PCR) to detect clonal immunoglobulin genes rearrangement was performed after laser microdissection on H&E-stained slides, using an LMD6 platform (Leica Microsystems, Germany).

Digital spatial profiling

The transcriptional landscape of 15 different spatially-resolved regions of interests (ROIs) of the tonsil (5 peri/inter-follicular ROIs, 5 DZ and 5 LZ ROIs from morphologically normal follicles) and 9 ROIs from the GEx was determined by Digital Spatial Profiling on slides stained with CD271/NGFR (as an FDC marker to highlight the LZ) and CD20 (as a B-cell marker). The 24 selected and segmented ROIs were profiled using a GeoMx Digital Spatial Profiler (DSP) (NanoString, Seattle WA) as previously described (7), applying the Cancer Transcriptome Atlas panel (https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-rna-assays/geomx-cancer-transcriptome-atlas/) (Supplementary Table 1).

Bioinformatic Data Analysis

After quality check step, raw counts were normalized against the 75th percentile of signal from their own ROI and normalized data were used to perform PCA using FactoMine R package. For hierarchical clustering analysis of the ROIs the Euclidean distance metric across samples

was considered and complete aggregation method was used for building tree within the R

package hclust.

Differential expression analyses were carried out by applying the moderated t-test using the

limma package (8); pairwise comparisons between GEx and DZ/LZ/Peri ROIs were

considered. Upregulated/downregulated genes were selected for subsequent analysis if their

expression values were found to exceed the threshold of 0.05 FWER (Bonferroni correction).

The spatial GEx signature was assessed in the following Schmitz et al. dataset (6) and the

clinical information was downloaded from the Schmitz et al. supplementary material.

After centering and scaling expression value, unsupervised hierarchical clustering analysis

based on the GEx signature was perform to identify potential discriminative clusters based on

Ward.D2 method on the Euclidean distance Survival analysis was performed using log-rank

test implemented in "survival" R package. Differences in patient characteristics among groups

were analyzed with the Fisher's exact test.

CIBERSORTx (http://cibersortx.stanford.edu) (9) has been used to calculate proportions of

microenvironment cell included in the LM22 signature on Schmitz *et al*. (6) RNA-seq data of

bulk tissues. This dataset was downloaded and analyzed using the authors' normalization

setting which included fragments per kilobase of transcript per million (FPKM) space. Bulk-

mode batch correction (B-mode) was applied to mixture samples before imputing cell fractions

and 1000 permutations were set for significance. Moreover, the SpatialDecon algorithm (10)

was additionally used for Nanostring data (safeTME profile matrix was applied). The

differences in CIBERSORTx cell fractions among clusters were investigated using the

Wilcoxon-Mann-Whitney test. Similarly, the differences in SpatialDecon cell fractions among

ROI subgroups were investigated using the Kruskal-Wallis test.

All statistical analyses have been performed using R statistical software (v4.0.2, http://www.R-

project.org).

Data Availability

Normalized gene expression data generated in the Digital Spatial Profiling experiment are

available in Supplementary Table 1

Results

Pathology of the tonsil

Histopathological analysis of the left tonsil from a young patient with clinical bilateral

hypertrophy revealed, in a background of lymphoid follicles with hyperplastic features and

preserved GC DZ, LZ and mantles, an isolated abnormal follicle with flattened mantle zone,

an enlarged GC without evident DZ/LZ polarization, preservation of rare tingible body

macrophages, and populated by a predominance of monomorphic plasmacytoid cells with

immature morphology (Figure 1A, inset). Quantitative immunophenotypical characterization

of reactive follicular (DZ and LZ) and peri-follicular (Peri) regions and of the atypical

germinotropic plasmablastic expansion (GEx), highlighted conspicuous differences in the

immune profile (Figure 1B-C). The reactive preserved GC DZ and LZ regions were

characterized by B cells with strong CD20 expression, dense Ki-67 immunoreactivity (higher

in the DZ), negativity for IRF4, except for scattered cells in a background of CD10-expressing

cells, Bcl-2 negativity, slight T-cell infiltration (denser in the LZ), and no evidence of light

chain restriction (Figure 1B-C). At contrast, the composition of the GEx displayed a CD20+ B

cell phenotype, high Ki-67+ proliferative fraction, diffuse IRF4 positivity with IRF4+ cells co-

expressing CD10, negativity for Bcl-2, and immunophenotypical restriction for lambda light

chain (Figure 1B-C). Most of the cells populating the GEx also expressed CD138 (in the

absence of CD30), indicating partial acquisition of a plasmablastic phenotype.

Immunoistochemistry for HHV8 and *in situ* hybridization for EBER (EBV) proved negative

(Supplementary Figure 1). On the basis of the GEx lambda light chain restriction, analysis of

the Ig light and heavy genes rearrangement was performed on DNA extracted by laser

microdissection of the GEx, which revealed a polyclonal profile (Supplementary Figure 2).

The strong and diffuse immunoreactivity of IRF4 and the co-occurrence of IRF4/CD10 double-

expressing elements prompted the analysis of *IRF4* gene rearrangement by fluorescence in situ

hybridization (FISH), which did not reveal any abnormality (Supplementary Figure 3),

allowing to exclude an *IRF4*-rearranged lymphoma.

Digital Spatial Profiling of the GEx regions reveals a distinctive profile

We subsequently investigated the in situ transcriptional profile of the GC plasmablastic burst

through the Nanostring GeoMx Digital Spatial Profiling technology. The expression of 1824

genes from key cancer-associated transcriptional programs (Supplementary Table 1) was

determined on 5 DZ, 5 LZ and 5 PERI ROIs selected from morphologically/phenotypically

preserved follicles/perifollicular areas, and on 9 GEx ROIs. We then asked whether GEx ROIs

could be defined by a specific gene signature; to this aim, principal component analysis (PCA)

and unsupervised hierarchical clustering were investigated. PCA revealed that ROIs segregated

according to their spatial classification, with PERI regions showing neatly separated profiles

from GC ROIs including DZ, LZ and GEx, which clustered together with other GC regions,

showing some degree of intermixing with LZ ROIs (Figure 2A). Consistently, clustering

analysis confirmed the same degree of relationship between the different ROIs (Figure 2B).

mRNA expression of the transcripts relative to the IHC markers evaluated for quantitative

immunopehnotypical analyses showed consistency with the protein expression pattern

(Supplementary Figure 4). Pairwise differential expression analysis performed on the different

ROIs allowed to identify candidate genes reflecting the distinctive profiles between the GEx

ROIs in comparison with DZ LZ and PERI ROIs (Figure 2C-F). Among the 20 differentially

expressed genes, 17 were significantly upregulated in GEx ROIs, while 3 were downmodulated

(Figure 2C-F). GEx hallmark genes included, along with the plasma cell differentiation

markers *PRDM1*, *IRF4*, *TNFRSF17* (BCMA) and *CD9*, genes involved in 2-oxoglutarate

metabolism (*GOT2*, *IDH2)*, in IL17 pathway (*IL17RB*, *HSP90B1*) and cytokine signaling

(*RASAL1*, *LTB*), in PI3K-Akt pathway (*SGK1, BCL2L1*), in lymphocyte activation (*ADA*,

SCL7A5, FCRL2) and cell surface regulation of immune activation (*CD24, LILRB1*), in cell

adhesion (*ANKRD28*) and response to abiotic (i.e. osmotic) stress (*SLK1*). Moreover, the long

non-coding RNA *FAM30* was also listed among the GEx hallmarks.

Spatial immune deconvolution of GEx ROIs shows enrichment in memory B cells and Plasma

cells

Based on the evidence of a distinct transcriptional profile of GEx regions in comparison with

other GC and perifollicular regions, we investigated the immune composition of the ROIs

according to transcriptional deconvolution. A SpatialDecon (10) approach using the safeTME

matrix was adopted, which highlighted that GEx ROIs displayed a different microenvironment

composition as compared with canonical LZ and DZ GC ROIs, also differing from peri-

follicular ROIs (Figure 3, Supplementary Table 2), further indicating that a perturbation of the

normal GC milieu. Specifically, GEx ROIs were positively enriched in Plasma cells and

memory B cells as compared with other ROIs (Kruskal-Wallis p-values < 0.001), while being

poorly infiltrated by T cells (Figure 2G).

The GEx signature outlines DLBCL clusters with different enrichment in genetic subtypes and

microenvironment composition

The molecular profiles of non-malignant GC compartments can be exploited to probe GC

microenvironment imprints in B-cell lymphomas with different degree of relationship with GC

subpopulations, such as DLBCL, in which the COO has shown prognostic significance in the

setting of standard chemo-immunotherapy regimens (7). To investigate whether the

transcriptional hallmarks identified in the GEx ROIs could be traced in the heterogeneous

spectrum of B-cell malignant transformation recapitulated by DLBCL, we applied the GEx

gene signature to a dataset of 481 DLBCL cases relative to Schmitz et al. (6). Based on the

expression of the 20 genes of the GEx signature, DLBCL clustered into two main groups

(Figure 3A), with the cluster 1 characterized by the overexpression of 17 genes

(Supplementary Figure 5A) and by a trend towards a worse prognosis (Supplementary Figure

5B-C). We subsequently investigated the distribution of the major DLBCL genetic subtypes

according to Schmitz and Colleagues (6) and found that the relative frequency of the subtypes

was significantly different in the two clusters identified by the GEx signature (Figure 3B-C,

Supplementary Tables 3 and 4). Specifically, cluster 1, which was characterized by the general

overexpression of hallmark genes of the GEx ROIs, showed a neat enrichment in cases with

MYD88 and *CD79B* mutation co-occurrence (MCD, Fisher p-value<10e-05), a higher

frequency of cases with BCL6 fusions and NOTCH2 mutations (BN2, Fisher p-value=0,02),

and a markedly lower frequency of cases with EZH2 and BCL2 lesions (EZB, Fisher p-

value<10e-9) (Figure 3C, Supplementary Tables 4) suggesting that the genes positively

characterizing GEx ROIs underlie a specific biology related with MCD genetics, known to be

enriched in ABC clones undergoing plasmablastic/plasmacytic commitment (6).

Prompted by the finding of a different microenvironment composition of GEx ROIs in

comparison with other GC and peri-follicular ROIs, we estimated the microenvironment of the

DLBCL clusters identified according to GEx signature, through CIBERSORTx deconvolution.

Consistently with the deconvolution of in situ transcriptional profiles of GEx ROIs, cluster 1,

which was characterized by up-regulation of GEx hallmark genes, showed a significant

enrichment in memory B cells and plasma cells (Mann-Whitney p-values < 0.001,

Supplementary Table 5), and a decrease in CD8 T cells and follicular T helper cells (Figure

3D), indicating that a link between the GEx that is a GC-related lsion, and lymphomatous

clones enriched in specific non-GC genetics, cell-of-origin and microenvironment, may exist.

Discussion

The transition of B cells undergoing selection and refinement of their IG receptor in the GC

reaction towards effectors capable of Ig secretion implies the acquisition of

plasmablastic/plasmacytoid features within the GC microenvironment. The spatial localization

of these functional and phenotypical intermediates is still poorly characterized and depends on

the dynamical modulation of chemotactic receptor/ligand axes interweaving with BCR-

controlled programs (11). Proliferating cells with plasmablastic/plasmacytoid features

accumulating within the GC therefore represents an element of atypia even in the setting of

non-clonal events, and little is known about the *molecular signature* characterizing their

transient state (12). In this report we phenotypically and transcriptionally characterized an

immunoglobulin light chain restricted non-clonal atypical germinotropic expansion of

plasmablastic cells, investigating differential features emerging from the comparison with

neighboring GC and extra-GC regions. The GEx ROIs were characterized by the unique co-

occurrence of IRF4 and CD10 expression, which highlighted a transitory state engendered by

IRF4 control of GC exit (13) and CD10 ectopeptidase retention that can be observed in DLBCL

with plasmablastic differentiation (14). On digital spatial profiling, a set of 20 genes were found

differentially expressed in GEx ROIs as compared with neighboring DZ, LZ and PERI ROIs.

The discriminating signature resulted positively enriched in the key transcription factors

driving plasma cell differentiation IRF4 and PRDM1, and included the B-cell differentiation

receptor BCMA involved in the transduction of trophic signals from APRIL and BAFF tumor

necrosis factor superfamily ligands (15). Such molecular features supportive of a plasmablastic

phenotype were also supported by the downregulation of CD24, a signal transducer negatively

modulated in response to BCR activation and along plasmablastic transition (16). The GC

localization of the plasmablastic expansion found resonance in the overexpression of CD9. The

tetraspanin CD9 has been reported to mark a subset of B cells in the human GC characterized

by plasmablastic differentiation and Blimp1 (*PRDM1*) expression (17). These CD9+ GC B

cells more efficiently give rise to CD20-CD38+ plasmablasts as compared with their CD9-

counterpart. Moreover, in the murine setting, the efficient plasmablastic/plasmacytic

differentiation of CD9+ B cells is shared by non-GC B-cells endowed with prompt commitment

to Ig-secreting effectors, such as B1 B cells and marginal zone B-cells subsets (18). By

applying the GEx differentially expressed genes signature to a well-characterized (both

transcriptionally and genetically) DLBCL dataset, we aimed at investigating whether the

atypical status of non-clonal germinotropic plasmablastic expansion could be represented in

the transcriptional signature of a subset of DLBCL of either ABC or GCB COO. Previous

reports described a subset of ABC-DLBCL expressing *PRDM1*/BLIMP1 and demonstrated

that loss of function of this antigen is harbinger of a poor prognosis (19). Expression of

IRF4/MUM1 is routinely employed in the diagnostic setting for the distinction of non-GC

subtypes based on immunohistochemical algorithms (20). Moreover, specific subtypes of large

B-cell lymphomas characterized by IRF4 rearrangement have been recently described and

recognized as independent entities in the most recent WHO classification (21). We report

additional molecular markers potentially associated with plasmablastic commitment in the GC,

including the receptor of IL17B/IL25 IL17RB, the overexpression of which marks

lymphoplasmacytic lymphomas with mutant $MYD88^{L265P}$ and $CXCR4^{WT}$ (22). In the GC

setting, IL17B/IL25 signaling could enforce NF-κB activity (23) through TRAF6, which

cooperation with CD40 signaling is required for B-cell affinity maturation and plasma cell

differentiation (24). From the genes positively and negatively characterizing GEx ROIs, no

relevant clues emerge about the mechanisms leading to the atypical GC retention and expansion

of the plasmablastic elements. Under normal conditions, the suppression of Bach2 and Pax5

transcripts, along with the down-regulation of Bcl-6, IRF8 and PU-1 and the activation of

BLIMP1 and MUM1/IRF4, drive the development of PCs resulting from the GC reaction (1).

Once their effector/memory fate is established, B cells escape from the GCs through the

suppression of the BCL-6-induced "confinement factor" S1PR2 and the expression of pro-

migratory receptors that are likely to be involved in GC exit, such as EBI2 and S1PR1 (25).

The downmodulation of lymphotoxin beta transcript emerging from the GEx ROIs profiling

can imply an impaired activation of the FDC meshwork by resident elements (26) which would

in turn impact on the maintenance of a functional GC microenvironment licensing atypical

plasmablastic expansion within the GC contexture. Indeed, some cases of abrupt/florid

follicular hyperplasia have been described in which activated B cells are mainly localized in

the GCs, partly twisting the normal follicular architecture and even showing

immunohistochemical light chain (oligoclonal) restriction, leading to diagnostic concern for

neoplasia (27). The perturbation of normal GC dynamics in GEx was also indicated by an

overall depletion in the Th compartment on transcriptional deconvolution analysis, which was

similar to that of the DZ, conflicting with the memory B and plasma cell enrichment. In

DLBCL, GEx hallmark genes identified a subgroup with positive enrichment in MCD genetics

and ABC COO, indicating that GC-related proliferations of plasmablastic elements may be

transcriptionally linked with non-GC DLBCL. These cases characterized by a dyscrasia

between cyto-architectural, phenotypical and topographic profile of a B-cell expansion with

plasmablastic/plasmacytic features may help in finding a link with the pathogenesis specific

DLBCL subsets (28) and reconcile an ABC-COO with GC-related lesions (29).

Acknowledgements

The Authors wish to acknowledge Prof. Maurilio Ponzoni for helpful discussion. This study

has been supported by the Italian Foundation for Cancer Research (AIRC) through the IG-2018

22145 Investigator Grant to C.T.; 5x1000 22759 Grant to C.T.; and by the Italian Ministry of

Education, University and Research (MIUR) grant 2017K7FSYB to C.T.

REFERENCES

1. De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015 Mar;15(3):137-48. doi: 10.1038/nri3804. Epub 2015 Feb 6. PMID: 25656706; PMCID: PMC4399774.

2. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity. 2007 Aug;27(2):190-202. doi: 10.1016/j.immuni.2007.07.009. PMID: 17723214; PMCID: PMC2242846.

3. Yam-Puc JC, Zhang L, Maqueda-Alfaro RA, Garcia-Ibanez L, Zhang Y, Davies J et al. Enhanced BCR signaling inflicts early plasmablast and germinal center B cell death. iScience. 2021 Jan 7;24(2):102038. doi: 10.1016/j.isci.2021.102038. PMID: 33552715; PMCID: PMC7822941.

4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503-11. doi: 10.1038/35000501. PMID: 10676951.

5. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30. Erratum in: Nat Med. 2018 Aug;24(8):1292. Erratum in: Nat Med. 2018 Aug;24(8):1290-1291. PMID: 29713087; PMCID: PMC6613387.

6. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445. PMID: 29641966; PMCID: PMC6010183.

7. Tripodo C, Zanardi F, Iannelli F, Mazzara S, Vegliante M, Morello G et al. A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. iScience. 2020 Sep 16;23(10):101562. doi: 10.1016/j.isci.2020.101562. PMID: 33083730; PMCID: PMC7522121.

8. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015 Apr 20;43(7):e47. doi: 10.1093/nar/gkv007. Epub 2015 Jan 20. PMID: 25605792; PMCID: PMC4402510.

9. Rusk, N. Expanded CIBERSORTx. *Nat Methods* **16,** 577 (2019). https://doi.org/10.1038/s41592-019-0486-8

10. Danaher, Kim et al., Advances in mixed cell deconvolution enable quantification of cell types in spatially-resolved gene expression data, BioRxiv, 2020, doi: https://doi.org/10.1101/2020.08.04.235168

11. Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C et al. The B-cell
receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. Nature.
2017 Jun 8;546(7657):302-306. doi: 10.1038/nature22353. Epub 2017 May 31. PMID:
28562582.

12. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J Jr. Gene expression profiling of
plasma cells and plasmablasts: toward a better understanding of the late stages of B-
cell differentiation. Blood. 2003 Jul 15;102(2):592-600. doi: 10.1182/blood-2002-10-
3161. Epub 2003 Mar 27. PMID: 12663452.

13. De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in late germinal
center B-cell differentiation. Immunol Rev. 2012 May;247(1):73-92. doi:
10.1111/j.1600-065X.2012.01113.x. PMID: 22500833.

14. Sonja Boy, Marlene van Heerden, Roger Pool, Pascale Willem & Tomas Slavik.
Plasmablastic lymphoma versus diffuse large B cell lymphoma with plasmablastic
differentiation: proposal for a novel diagnostic scoring system. Journal of
Hematopathology volume 8, pages 3–11 (2015). DOI 10.1007/s12308-014-0227-y.

15. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C et al. BCMA
is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004
Jan 5;199(1):91-8. doi: 10.1084/jem.20031330. PMID: 14707116; PMCID:
PMC1887725.

16. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Rème T et al. Characterization of a
transitional preplasmablast population in the process of human B cell to plasma cell
differentiation. J Immunol. 2011 Oct 15;187(8):3931-41. doi:
10.4049/jimmunol.1101230. Epub 2011 Sep 14. PMID: 21918187.

17. Yoon SO, Zhang X, Lee IY, Spencer N, Vo P, Choi YS. CD9 is a novel marker for
plasma cell precursors in human germinal centers. Biochem Biophys Res Commun.
2013 Feb 1;431(1):41-6. doi: 10.1016/j.bbrc.2012.12.102. Epub 2013 Jan 3. PMID:
23291167; PMCID: PMC3563937.

18. Won WJ, Kearney JF. CD9 is a unique marker for marginal zone B cells, B1 cells, and
plasma cells in mice. J Immunol. 2002 Jun 1;168(11):5605-11. doi:
10.4049/jimmunol.168.11.5605. PMID: 12023357.

19. Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V et al. Loss of
PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like
diffuse large B-cell lymphoma. Leukemia. 2017 Mar;31(3):625-636. doi:
10.1038/leu.2016.243. Epub 2016 Aug 29. PMID: 27568520; PMCID: PMC5837859.

20. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al.
Confirmation of the molecular classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 2004 Jan 1;103(1):275-82.
doi: 10.1182/blood-2003-05-1545. Epub 2003 Sep 22. PMID: 14504078.
430

21. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed.; IARC: Lyon, France, 2017.

22. Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X et al. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 Aug 11;128(6):827-38. doi: 10.1182/blood-2016-03-708263. Epub 2016 Jun 14. PMID: 27301862; PMCID: PMC4982454.

23. Maezawa Y, Nakajima H, Suzuki K, Tamachi T, Ikeda K, Inoue J et al. Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J Immunol. 2006 Jan 15;176(2):1013-8. doi: 10.4049/jimmunol.176.2.1013. PMID: 16393988.

24. Ahonen C, Manning E, Erickson LD, O'Connor B, Lind EF, Pullen SS et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol. 2002 May;3(5):451-6. doi: 10.1038/ni792. Epub 2002 Apr 22. PMID: 11967542; PMCID: PMC2834483.

25. Green JA, Cyster JG. S1PR2 links germinal center confinement and growth regulation. Immunol Rev. 2012 May;247(1):36-51. doi: 10.1111/j.1600-065X.2012.01114.x. PMID: 22500830; PMCID: PMC3335345.

26. Myers RC, King RG, Carter RH, Justement LB. Lymphotoxin α1β2 expression on B cells is required for follicular dendritic cell activation during the germinal center response. Eur J Immunol. 2013 Feb;43(2):348-59. doi: 10.1002/eji.201242471. Epub 2012 Dec 5. PMID: 23112125; PMCID: PMC3753018.

27. Gars E, Butzmann A, Ohgami R, Balakrishna JP, O'Malley DP. The life and death of the germinal center. Ann Diagn Pathol. 2020 Feb;44:151421. doi: 10.1016/j.anndiagpath.2019.151421. Epub 2019 Nov 13. PMID: 31751845.

28. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020 Apr 13;37(4):551-568.e14. doi: 10.1016/j.ccell.2020.03.015. PMID: 32289277.

29. Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z et al. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov. 2021 Jun;11(6):1468-1489. doi: 10.1158/2159-8290.CD-20-0839. Epub 2021 Feb 4. PMID: 33541860; PMCID: PMC8178179.

Figure 1

A, Digitalized slide selection of the Haematoxylin and Eosin (H&E)-stained section of the tonsil highlighting the presence of an aberrantly expanded germinal center (asterisk) characterized by the presence of elements with plasmacytoid morphology (inset). On the H&E, representative regions relative to germinal center dark zone (DZ) and light zone (LZ) areas, peri-follicular (Peri) areas, and germinotropic plasmablastic expansion (GEx) areas, are highlighted. Original magnification x50. **B**, Comparative analysis of H&E and IHC for Bcl-2, Bcl-6, CD3, CD20, Kappa and Lambda light chain, Ki67, IRF4, IRF4/CD10, CD2, CD138 in the DZ, LZ, Peri and GEx areas highlighted in A. **C,** Heatmap of the average expression of the quantitative immunohistochemical analysis of the markers evaluated in the DZ, LZ, Peri, and GEx areas highlighted in B.

Figure 2

A, Two-dimensional principal component reduction of the DZ (n=5), LZ (n=5), Peri (n=5), and GEx (n=9) regions of interest (ROIs) profiles according to Digital Spatial Profiling of 1824 genes. **B**, Unsupervised hierarchical clustering of the 24 ROIs. **C**, Venn diagram of UP-modulated genes from three different comparisons (i.e., GEx vs DZ, GEx vs LZ, and GEx vs Peri). **D**, Venn diagram of DOWN modulated genes from three different comparisons (i.e., GEx vs DZ, GEx vs LZ, and GEx vs Peri). **E**, GEx signature genes. These genes are significantly differentially expressed in GEx in each comparison. **F**, Heatmap of differentially expressed genes in GEx as compared to DZ, LZ and Peri ROIs. The GEx signature shows a high discriminatory capacity between GEx ROIs and the other regions. **G**, Average SpatialDecon fractions of cell types in the four ROI subgroups. Kruskal-Wallis test has been applied to compare faction distributions among groups (Supplementary table 2).

Figure 3

A, Unsupervised clustering analysis of the 481 DLBCL cases based on the GEx signature. It identifies two distinct clusters; the blue one is characterized by a higher gene expression, while a lower gene expression characterizes the green one. **B**, Barplot of cell of origin (COO) absolute frequencies observed among clusters. Cluster 1 is enriched by ABC cases, whereas cluster 2 is enriched by GCB cases (Fisher p-values < 10e-15). **C**, Barplot of genetic subtypes absolute frequencies observed among clusters (Fisher p-values reported in Supplementary Table 3). **D**, Average CIBERSORTx fractions of cell types in the four ROI subgroups. Wilcoxion-Mann-Withney test has been applied to compare faction distributions among groups (Supplementary Table 4).

Figure 1

A

B

C

Figure 2

Figure 3

A

B

COO frequences

C

Genetic subtypes frequences

D

Average CIBERSORTx fractions over 481 DLBCL cases